Beyond Precision: The New Paradigm of Radiation Oncology in Prostate Cancer in Costa Rica

Prostate cancer remains one of the most common malignancies worldwide and a growing health concern in Costa Rica, particularly in the context of an aging population. Within this landscape, Radiation Oncology has undergone a profound transformation, evolving from conventional techniques into a highly sophisticated discipline that integrates technological precision with biological understanding of disease behavior.

Historically, radiotherapy relied on prolonged treatment schedules with small daily fractions. However, advances in radiobiology have demonstrated that prostate cancer has a low alpha/beta ratio, making it particularly sensitive to higher doses per fraction. This insight has driven the development of moderate and ultra-hypofractionated radiotherapy, which has shown comparable oncologic outcomes to conventional regimens while significantly reducing treatment duration and improving patient convenience .

At the same time, technological progress has revolutionized radiation delivery. Techniques such as IMRT, VMAT, and SBRT have enhanced dose conformity, allowing for precise targeting of tumors while minimizing exposure to surrounding organs like the rectum and bladder . These advances have enabled the safe implementation of more intensive treatment strategies without substantially increasing toxicity.

Yet, one of the most important shifts in recent years is not purely technological but conceptual. The PEACE V–STORM trial, published in The Lancet Oncology (2025), demonstrated that treating only visible nodal recurrences may be insufficient. In this study, elective nodal radiotherapy to the pelvis resulted in improved disease control compared to metastasis-directed therapy alone. This finding challenges the assumption that imaging fully captures disease extent and highlights the importance of addressing subclinical microscopic disease.

For clinical practice in Costa Rica, these developments carry significant implications. The integration of advanced radiotherapy with broader treatment strategies allows for more comprehensive oncologic management. Furthermore, modern care increasingly relies on a multidisciplinary approach, where radiologists, medical oncologists, urologists, and radiation oncologists collaborate to design personalized treatments guided by advanced imaging modalities such as multiparametric MRI and PSMA PET .

Despite these advances, important challenges remain. Patient selection, toxicity management, and integration with systemic therapies continue to require careful consideration. Emerging technologies such as MR-guided radiotherapy, proton therapy, and radioligand therapy are expected to further reshape the therapeutic landscape in the coming years.

The management of prostate cancer is evolving toward a more integrated model in which technical precision is combined with a broader biological strategy. In Costa Rica, Radiation Oncology is well positioned to adopt these innovations and improve patient outcomes. The challenge today is no longer just to treat what is visible, but to anticipate and address disease that remains unseen.